Stocksigma LogoStocksigma Logo

Vanta Bioscience Reports FY26 Results and Re-appoints Managing Director

Vanta Bioscience approved its audited FY26 results on 30 May'26. On a consolidated basis, FY26 revenue was Rs

Vanta Bioscience Reports FY26 Results and Re-appoints Managing Director

Vanta Bioscience Ltd 路 Financial Result 路 31 May 2026, 2:05 am

Vanta Bioscience Reports FY26 Results and Re-appoints Managing Director Vanta Bioscience approved its audited FY26 results on 30 May'26. On a consolidated basis, FY26 revenue was Rs. 197.59 Lacs, with a net profit after tax of Rs. 10.83 Lacs, a significant turnaround from the Rs. 267.09 Lacs loss in FY25. For H2 FY26, the company posted a net profit of Rs. 192.72 Lacs. The Board also approved the re-appointment of Mr. Dopesh Raja Mulakala as Managing Director for three years, effective 18 Apr'26. The statutory auditor provided an unqualified opinion on the financial statements.

Original exchange filing (PDF)

More announcements from Vanta Bioscience Ltd

All Vanta Bioscience Ltd announcements